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Introduction:We previously showed that squamous cell carcinoma
(SCC) patients with directly involved N1 nodes resulted in outcomes
significantly better than those with separately involved N1 nodes.
The purpose of this study was to evaluate the prognostic effect of
node involvement patterns in pN1 non-small cell lung cancer
(NSCLC) patients, with special attention given to any differences
between SCC and adenocarcinoma (AD).
Methods: We reviewed 324 consecutive patients with completely
resected pN1 NSCLC and classified them into two groups based on
their node involvement patterns: directly or separately involved N1
groups. To compare survival rates, 1545 pN0 patients and 330 pN2
patients were also investigated.
Results: Univariate and multivariate analyses showed that the node
involvement pattern was significantly associated with pN1 NSCLC
patient outcome. The directly involved N1 group had a much better
5-year overall survival rate of 60.1% compared with 45.0% for the
separately involved N1 group. In SCC patients, the directly involved
N1 group showed an overall survival similar to pN0 patients,
whereas overall survival of the separately involved N1 group was
identical to that of pN2 patients, and their survival rates were
significantly different. In AD patients, however, the survival rates
were marginally different between the directly and separately in-
volved N1 groups, and they were intermediate between pN0 and
pN2 patient survival rates.
Conclusions: Node involvement patterns had significant prognostic
effect in pN1 NSCLC patients. This effect was different between
SCC and AD cases. The subclassification of N1 based on node
involvement pattern is of significance for SCC patients but not for
AD patients.
(J Thorac Oncol. 2010;5: 1576–1582)
Lymph node involvement is one of the most common andimportant prognostic factors in solid cancers of a wide
variety of organs. It is categorized based on its anatomic
extent by the N classification in the tumor, node, metasta-
sis (TNM) classification of the Union Internationale Con-
tre le Cancer (UICC).1 There are two ways for cancer cells
to metastasize from the primary tumor to a lymph node.
One is by lymphatic flow: cancer cells invade lymphatic
ducts, travel through the lymphatic flow, and become
implanted in a lymph node that is separate from the
primary tumor. The other way is by direct invasion to an
adjacent node without any intervening pathways. Although
it is possible that the prognostic effect of direct node
involvement by the primary tumor may be different from
that of node involvement separated from the primary
tumor, nothing regarding this possibility is suggested in
the seventh edition of the TNM Classification for Lung and
Pleural Tumors on N1 (peribronchial, interlobar, or peri-
hilar) lymph node involvement patterns.2
In our previous study, we investigated 120 patients
with completely resected pathologic N1 (pN1) squamous
cell carcinoma (SCC) and classified them into two groups
based on N1 node involvement patterns: direct or separate.
The SCC patients with directly involved N1 nodes had a
much better 5-year overall survival rate of 67.7%, similar
to pN0 patients, compared with 32.4% for patients with
separately involved N1 nodes, a finding that was similar to
pN2 patients. We concluded that directly involved N1 is
local disease and separately involved N1 is systemic dis-
ease. Although they are currently categorized as the same
N1 classification, the N1 involvement pattern may be
incorporated in future non-small cell lung cancer (NSCLC)
staging systems.3
SCC arises in the central airways adjacent to hilar
lymph nodes, more frequently than other histologic types,4
and two-thirds (80 of 120) of the pN1 patients showed
direct node invasion in our previous study.3 In contrast,
most cases of adenocarcinoma (AD), the most common
histologic type of lung cancer, arise in the lung periphery,
and direct N1 involvement is likely to be rarer than
separate N1 involvement. However, peripheral AD some-
times involves the lobar, segmental, or subsegmental
lymph nodes, either directly or separately, but they are also
categorized as the same N1. It is also unclear how lymph
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node involvement pattern influences pN1 NSCLC patient
outcomes, especially when stratified by histologic type.
The purpose of this study was to evaluate the prog-
nostic effect of lymph node involvement patterns in pN1
NSCLC patients, with special attention given to any dif-
ferences between SCC and AD.
PATIENTS AND METHODS
Patients
At our institution, 2546 consecutive primary lung
cancer patients underwent surgical resection between July
1992 and December 2005. Among them, a total of 331
patients, without any preoperative anticancer treatments in
whom resection was considered complete and whose dis-
ease was pathologically diagnosed as N1 NSCLC, were
identified. We defined complete resection as either lobec-
tomy or more extensive resection with systematic ipsilat-
eral hilar and mediastinal lymph node dissection and an
absence of residual cancer both macroscopically and his-
tologically. We excluded seven patients because of incom-
plete pathologic records, and the remaining 324 patients
were the subject of this study. To compare the survival
probability rates, 1545 and 330 NSCLC patients, com-
pletely resected during the same period and diagnosed as
pN0 and pN2, respectively, were also investigated. We
reviewed the medical records of all patients for the fol-
lowing clinicopathologic factors: age, gender, smoking
index, preoperative serum carcinoembryonic antigen level,
location, type of resection, pathologic T classification,
tumor size, histologic type, lymphatic infiltration, vascular
invasion, pleural invasion, level 10 node involvement, and
number of involved N1 nodes.
Lymph nodes that were larger than 1.0 cm in mini-
mum dimension on preoperative contrast-enhanced com-
puted tomography were clinically diagnosed as involved.
Clinical N classification and pathologic stage were deter-
mined according to the UICC TNM Classification for Lung
and Pleural Tumors.1 We defined tumor location as central
if the primary tumor arose in the main, lobar, or segmental
bronchi and as peripheral if the primary tumor was located
distally to the subsegmental bronchi.
Histopathologic Evaluation
All resected specimens were fixed with 10% formalin
and embedded in paraffin. The main tumors were sliced at
approximately 5-mm intervals, and serial 4-m sections were
stained using hematoxylin and eosin for routine pathologic
evaluation, the Alcian blue-periodic acid-Schiff staining
method for cytoplasmic mucin production, and the elastica-
van Gieson or Victoria blue van Gieson method for elastic
fibers. Lymphatic infiltration was considered to be present
when tumor cells were identified floating in lymphatic vessels
defined by the lack of supporting smooth muscles or elastic
fibers in the vessel wall. Vascular invasion was considered to
be present when tumor cells were identified floating in blood
vessels defined by supporting elastic fibers in the vessel wall.
Pleural invasion was considered to be present when tumor
cells were identified beyond the elastic layer of the visceral
pleura, regardless of tumor exposure on the pleural surface.5
Histologic classification of the resected specimens was deter-
mined according to the World Health Organization Interna-
tional Histologic Classification of Tumors.6
Lymph Node Involvement
Pathologic lymph node involvement was evaluated in
the same manner as described in our previous study.3 Lymph
node stations were designated according to the lymph node
map created by Naruke et al.,7 and level 10 nodes were
defined as main bronchial nodes. We classified involved
lymph nodes into two patterns according to the relationship
between the main tumor and lymph nodes on resected spec-
imens. We defined one pattern as “direct N1” node, an N1
node completely inside of, or partly connected to, the primary
tumor. Considering the 5-mm specimen slice interval, lymph
nodes that were 3 mm or less distant from the main tumor
were also classified as direct N1 even if the tumor did not
seem to be in direct contact with the N1 nodes on the resected
specimen. The other pattern, a “separate N1” node, was
defined as an N1 node that was connected with the primary
tumor only by preexisting normal bronchovascular structures
and located more than 3 mm away from the main tumor. We
classified the 324 pN1 NSCLC patients into two groups:
patients whose involved N1 nodes were all direct N1 nodes
were classified as the direct group, and those with at least one
separate N1 node were classified as the separate group.
Statistical Analysis
Either the 2 test or Fisher’s exact test was used to
analyze any correlation between the N1 node involvement
patterns and clinicopathologic factors. We used the Cox’s
proportional hazards regression model to identify statistically
significant differences in survival and to estimate hazard
ratios and 95% confidence intervals. Survival curves were
plotted using the Kaplan-Meier method, and the statistical
significance of differences between subgroups was deter-
mined by the log-rank test. The end point for analyses was
overall survival, measured from the date of surgery to the
date of death from any cause. The last follow-up observation
was censored when the patient was alive or lost to follow-up.
All p values were two sided, and p values less than 0.05 were
considered to indicate a statistically significant difference.
We used statistical analysis software (Dr. SPSS II for Win-
dows, Standard Version 11.0, SPSS Inc., Chicago, IL) for
these analyses. Data collection and analyses were approved,
and the need to obtain written informed consent from each
patient was waived by the institutional review board in
January 2010.
RESULTS
N1 Node Involvement Patterns and
Clinicopathologic Factors
The clinicopathologic characteristics of the 324 pN1
NSCLC patients are shown in Table 1, and detailed charac-
teristics of node involvement are shown in Table 2. Tumor
size cutoff was set at the median of 4.0 cm. Because the
median number of involved N1 nodes was two, we divided
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the patients into single or multiple node involvement groups.
The correlations between node involvement pattern and other
clinicopathologic factors with a p value less than 0.1 are
shown in Table 3. The direct N1 node involvement pattern
was statistically significantly correlated with male gender,
high smoking index, central location, pneumonectomy,
higher pT classification, larger tumor size, SCC histologic
type, presence of pleural invasion, and the absence of level 10
node involvement.
Histopathological Comparison of pN1 NSCLC
AD and SCC, the predominant histologic types of
NSCLC, accounted for 52 and 37% of all cases, respectively.
We compared them in relation to clinicopathologic factors,
and factors with a p value less than 0.1 are shown in Table 4.
In the AD patient group, there were significantly more
woman, patients who had undergone lobectomy, patients
classified as pT1, those with a smaller tumor size, lymphatic
infiltration, peripheral tumor location, and separate node
involvement, compared with the SCC patient group. In con-
trast, there were significantly more man, patients with a heavy
smoking history, patients who had undergone pneumonec-
tomy, those with larger tumor size, central tumor location,
and direct node involvement, compared with the AD patient
group.
Prognostic Effect of N1 Node Involvement
Pattern on Survival
The median length of overall follow-up period for the
censored patients was 5.4 years. Univariate analysis showed
that patient survival was significantly associated with the N1
node involvement pattern, as well as tumor location, tumor
size, and pleural invasion, and marginally associated with age
and lymphatic infiltration. Age was dichotomized at the
median of 65 years. Among the six prognostic factors in the
univariate analysis, multivariate analysis showed larger tu-
mor size and node involvement pattern to be independent
predictors of poor outcome (Table 5).
Survival curves according to pathologic N classifi-
cation of NSCLC patients are shown in Figure 1. The
5-year overall survival rate of pN1 patients (51.3%) was
significantly lower than that of pN0 patients (77.5%) and
higher than that of pN2 patients (27.9%; Figure 1A). When
the direct and separate N1 groups were compared, the
direct N1 group showed a significantly better 5-year
overall survival rate of 60.1% compared with 45.0%
of the separate N1 group. These survival curves were
TABLE 1. Clinicopathologic Characteristics of pN1 NSCLC
Patients
Patients (n  324)
n (%)
Age (yr)
Median 65
Range 36–83
Gender
Women 80 (25)
Men 244 (75)
Smoking index (pack-years)
20 91 (28)
20 233 (72)
CEA (ng/dl)a
5 145 (45)
5 178 (55)
Location
Central 102 (31)
Peripheral 222 (69)
Type of resection
Lobectomy 231 (71)
Bilobectomy 31 (10)
Pneumonectomy 62 (19)
pT classification
T1 76 (23)
T2 167 (52)
T3 54 (17)
T4 27 (8)
Tumor size (cm)
4 185 (57)
4 139 (43)
Histological type
Adenocarcinoma 168 (52)
Squamous cell carcinoma 120 (37)
Large cell carcinoma 19 (6)
Adenosquamous carcinoma 10 (3)
LCNEC 4 (1)
Pleomorphic carcinoma 3 (1)
Lymphatic infiltration
Absent 129 (40)
Present 195 (60)
Vascular invasion
Absent 61 (19)
Present 263 (81)
Pleural invasion
Absent 155 (48)
Present 169 (52)
Values are given as n (%).
a Data not available for one patient.
CEA, preoperative serum carcinoembryonic antigen level; LCNEC, large cell
neuroendocrine carcinoma; NSCLC, non-small cell lung cancer.
TABLE 2. Node Involvement Characteristics of pN1
NSCLC Patients
Patients (n  324)
n (%)
Level 10 node involvement
Present 44 (14)
Absent 280 (86)
Number of involved N1 nodes
Single 156 (48)
Multiple 168 (52)
Node involvement pattern
Direct 130 (40)
Separate 194 (60)
NSCLC, non-small cell lung cancer.
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clearly separated in the order of pN0, direct pN1, separate
pN1, and pN2 with statistically significant differences
(Figure 1B).
Figure 2 shows evident differences in the prognostic
effect of node involvement patterns according to histologic
type. In SCC patients, as we previously reported, the direct
N1 group had a significantly better 5-year overall survival
rate of 67.7% compared with 32.4% of the separate N1
group. The direct N1 group survival curve almost com-
pletely overlapped the pN0 curve, whereas the separate N1
group curve overlapped the pN2 curve (Figure 2A). In AD
patients, however, the prognostic difference was marginal
between the direct N1 and separate N1 groups (p  0.06).
The survival rates of these two groups were significantly
lower than those of the pN0 patients and higher than those
of the pN2 patients (Figure 2B).
We did not analyze other histologic types separately
because of their diversity and the small number of patients
of each histologic type.
DISCUSSION
In the UICC TNM classification, lymph node in-
volvement is categorized based on anatomic extent, and a
new lymph node map, reconciling the Naruke et al.7 and
AJCC8 maps, was adopted for the seventh edition.2 How-
ever, the N1 node involvement pattern has never been
considered in the TNM classifications. In a previous study,
we showed the prognostic effect of node involvement
patterns in pN1 SCC patients and suggested that it should
be incorporated into future NSCLC staging systems. In this
TABLE 3. Correlations Between Node Involvement
Patterns and Clinicopathologic Factors
Node Involvement
Pattern
p
Direct
(n  130)
Separate
(n  194)
Gender
Women 21 59
Men 109 135 0.01
Smoking index (pack-years)
20 21 70
20 109 124 0.01
Location
Central 83 19
Peripheral 47 175 0.01
Type of resection
Lobectomy 69 162
Bilobectomy 15 16
Pneumonectomy 46 16 0.01
pT classification
T1 21 55
T2 70 97
T3 30 24
T4 9 18 0.01
Tumor size (cm)
4 60 125
4 70 69 0.01
Histologic type
Adenocarcinoma 33 135
Squamous cell carcinoma 80 40
Others 17 19 0.01
Lymphatic infiltration
Absent 60 69
Present 70 125 0.06
Pleural invasion
Absent 74 81
Present 56 113 0.01
Level 10 node involvement
Present 10 34
Absent 120 160 0.01
No. of involved N1 nodes
Single 71 85
Multiple 59 109 0.07
LCNEC, large cell neuroendocrine carcinoma.
TABLE 4. Comparison Between pN1 Adenocarcinoma and
Squamous Cell Carcinoma Patients
Histological Type
p
AD
(n  168)
SCC
(n  120)
Gender
Women 66 8
Men 102 112 0.01
Smoking index (pack-years)
20 78 9
20 90 111 0.01
Location
Central 18 73
Peripheral 150 47 0.01
Type of resection
Lobectomy 149 62
Bilobectomy 10 17
Pneumonectomy 9 41 0.01
pT classification
T1 51 20
T2 85 63
T3 11 31
T4 21 6 0.01
Tumor size (cm)
4 118 57
4 50 63 0.01
Lymphatic infiltration
Absent 55 57
Present 113 63 0.01
Vascular invasion
Absent 40 18
Present 128 102 0.08
Node involvement pattern
Direct 33 80
Separate 135 40 0.01
AD, adenocarcinoma; SCC, squamous cell carcinoma.
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study, we showed the prognostic effect of node involve-
ment patterns in pN1 NSCLC patients. Although the over-
all survival rates were significantly different between the
direct and separate pN1 groups for all NSCLC patients, its
effect on prognosis was different from that of our previous
study, which was limited to SCC patients.
Analysis according to histologic type of NSCLC
showed a different effect on prognosis between SCC and
AD. In SCC patients, the results suggest that direct N1
disease may be due to direct cancer invasion and remain
local without lymphatic extension, similar to pN0 disease,
whereas separate N1 disease is systemic with lymphatic
extension, similar to pN2 disease. We speculate that these
differences were in part due to differences in the ability to
grow independently of cell anchorage, which is an impor-
tant feature for cancer cells to avoid anoikis and metasta-
size.9 In the direct N1 group, SCC cells may lack this
feature and be therefore unable to spread beyond directly
involved nodes. We conclude that these two SCC groups
need to be categorized into different N classifications and
not as the same N1.
In contrast, in AD patients, the direct and separate
N1 group survival rates were not significantly different and
were intermediate between pN0 and pN2 patients. These
results suggest that even in direct N1 involvement patients,
AD cells can be exfoliated and transported by the lym-
phatic flow as in separate N1 patients but not as much as
in pN2 patients. We speculate that AD cells, compared
with SCC cells, have greater potential to invade the lym-
phatics and become implanted in the lymph nodes and
distant organs, acquiring anchorage-independent growth
ability earlier in the tumor progression. This may explain
the outcome similarity between the direct and separate
pN1 AD patients. Because AD patients accounted for more
than half of the study cohort, outcome, when analyzed
collectively for NSCLC patients, was found to differ from
our previous study, which was limited to SCC patients.
Several researchers have reported that pN1 node
involvement pattern is associated with patient prognosis.
van Velzen et al.10–12 analyzed the association between
FIGURE 1. Overall survival curves of pN0 to pN2
non-small cell lung cancer patients. Overall sur-
vival curves of pN0, pN1, and pN2 patients (A).
Overall survival curves of direct and separate N1
groups compared with pN0 and pN2 patients (B).
TABLE 5. Prognostic Significance in Overall Survival
Univariate Analysis Multivariate Analysis
Number 5-yr (%) p HR 95% CI p
Age (yr)
64 146 56.9 1
65 178 46.8 0.06 1.307 0.959–1.783 0.90
Location
Central 102 63.2 1
Peripheral 222 45.9 0.01 1.372 0.892–2.111 0.15
Tumor size (cm)
4 185 55.9 1
4 139 45.0 0.04 1.525 1.101–2.113 0.01
Lymphatic
infiltration
Absent 129 57.7 1
Present 195 47.4 0.06 1.276 0.923–1.765 0.14
Pleural invasion
Absent 155 56.3 1
Present 169 46.6 0.04 1.097 0.795–1.513 0.57
Node involvement
pattern
Direct 130 60.1 1
Separate 194 45.0 0.01 1.559 1.035–2.350 0.03
5-yr, 5-yr overall survival rate; HR, hazard ratio; CI, confidence interval.
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pN1 involvement patterns and NSCLC patient survival in
T1, T2, and T3 to T4 patients separately and found
statistically significant associations only in pT1N1M0 pa-
tients. Marra et al.13 reported a significant correlation
between lymphatic spread pattern and prognosis. They
reported that an incidence of direct node involvement was
higher in SCC (53%) than in AD (32%) and suggested that
it was due to difference in tumor location. Our results were
comparable with theirs, with direct node involvement
found in 67 and 20% in SCC and AD, respectively.
However, in these previous studies, pN1 patients were not
compared with other N classifications. This study includes
outcome comparison with pN0 and pN2 patients and sep-
arate analyses for SCC and AD.
Advances in molecular technology have increased
our knowledge of lung cancer biology, and differences
between AD and SCC have been identified. The identifi-
cation of epidermal growth factor receptor (EGFR) led to
EGFR-tyrosine kinase inhibitor development, and EGFR
gene mutations explain why EGFR-tyrosine kinase inhib-
itor has specific therapeutic effects in some AD pa-
tients.14,15 Pemetrexed has been shown to have a signifi-
cant therapeutic effect in advanced nonsquamous cancers
but not in SCC.16,17 High thymidylate synthase expression
in SCC was reported to be a possible explanation for this
difference.18 These findings demonstrate that the current
histologic grouping of small cell lung cancer and NSCLC
is insufficient when choosing the optimal chemotherapy
regimen. Our results highlighted differences in biologic
behavior between AD and SCC, which may help better
evaluate pN1 status and stage diseases differently accord-
ing to histologic type.
CONCLUSIONS
Lymph node involvement pattern had a statistically
significant prognostic effect in pN1 NSCLC patients, and it
was significantly different between SCC and AD. The
prognostic effect of node involvement patterns was signif-
icant in SCC patients but marginal in AD patients. These
results suggest that the invasive and metastatic potential of
AD and SCC differs. The subclassification of N1 based on
node involvement pattern is statistically significant for
SCC patients but not for AD patients. Further study in a
larger cohort and involving multiple institutions is essen-
tial to verify these findings and to incorporate N1 involve-
ment pattern and histology in future NSCLC staging sys-
tems.
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